752 related articles for article (PubMed ID: 28794381)
1. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission after Six Months of Non-tumor Necrosis Factor Biological Disease-Modifying Antirheumatic Drugs (DMARDs) Treatment.
Miwa Y; Saito M; Furuya H; Yanai R; Ikari Y; Hayashi T; Kasama T; Toyoshima Y; Inagaki K
Intern Med; 2017 Sep; 56(17):2271-2275. PubMed ID: 28794381
[TBL] [Abstract][Full Text] [Related]
2. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission with Six Months of Biological DMARDs Treatment.
Miwa Y; Takahashi R; Ikari Y; Maeoka A; Nishimi S; Oguro N; Hayashi T; Hatano M; Isojima S; Yanai R; Kasama T; Toyoshima Y; Inagaki K; Sanada K
Intern Med; 2017; 56(8):903-906. PubMed ID: 28420837
[TBL] [Abstract][Full Text] [Related]
3. Comparison of physical function in early rheumatoid arthritis patients treated with biologics for 1 year who achieved clinical remission or low disease activity.
Hattori Y; Kida D; Kaneko A
Clin Rheumatol; 2017 Nov; 36(11):2607-2612. PubMed ID: 28823077
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching.
Kubo S; Nakayamada S; Nakano K; Hirata S; Fukuyo S; Miyagawa I; Hanami K; Saito K; Tanaka Y
Ann Rheum Dis; 2016 Jul; 75(7):1321-7. PubMed ID: 26245754
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
Bergman M; Tundia N; Martin N; Suboticki JL; Patel J; Goldschmidt D; Song Y; Wright GC
Arthritis Res Ther; 2022 Jun; 24(1):155. PubMed ID: 35751108
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis.
Jansen JP; Buckley F; Dejonckheere F; Ogale S
Health Qual Life Outcomes; 2014 Jul; 12():102. PubMed ID: 24988902
[TBL] [Abstract][Full Text] [Related]
7. Differences in Predictive Factors for Sustained Clinical Remission with Abatacept Between Younger and Elderly Patients with Biologic-naive Rheumatoid Arthritis: Results from the ABROAD Study.
Sekiguchi M; Fujii T; Matsui K; Murakami K; Morita S; Ohmura K; Kawahito Y; Nishimoto N; Mimori T; Sano H;
J Rheumatol; 2016 Nov; 43(11):1974-1983. PubMed ID: 27585689
[TBL] [Abstract][Full Text] [Related]
8. Routine Assessment of Patient Index Data 3 and the American College of Rheumatology/European League Against Rheumatism Provisional Remission Definitions as Predictors of Radiographic Outcome in a Rheumatoid Arthritis Clinical Trial With Tocilizumab.
Khawaja MN; Bergman MJ; Yourish J; Pei J; Reiss W; Keystone E
Arthritis Care Res (Hoboken); 2017 May; 69(5):609-615. PubMed ID: 27564431
[TBL] [Abstract][Full Text] [Related]
9. Physician global assessment at 3 months is strongly predictive of remission at 12 months in early rheumatoid arthritis: results from the CATCH cohort.
Choy T; Bykerk VP; Boire G; Haraoui BP; Hitchon C; Thorne C; Keystone EC; Pope JE;
Rheumatology (Oxford); 2014 Mar; 53(3):482-90. PubMed ID: 24241035
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
11. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
Ciubotariu E; Gabay C; Finckh A;
J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
[TBL] [Abstract][Full Text] [Related]
12. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
Mancarella L; Bobbio-Pallavicini F; Ceccarelli F; Falappone PC; Ferrante A; Malesci D; Massara A; Nacci F; Secchi ME; Manganelli S; Salaffi F; Bambara ML; Bombardieri S; Cutolo M; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Grassi W; Lapadula G; Cerinic MM; Montecucco C; Trotta F; Triolo G; Valentini G; Valesini G; Ferraccioli GF;
J Rheumatol; 2007 Aug; 34(8):1670-3. PubMed ID: 17611987
[TBL] [Abstract][Full Text] [Related]
13. No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study.
Kim SK; Choe JY; Park SH; Lee H
Clin Rheumatol; 2016 May; 35(5):1129-36. PubMed ID: 26932795
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
[TBL] [Abstract][Full Text] [Related]
15. The durability of abatacept as a first and subsequent biologic and improvement in HAQ from a large multi-site real-world study.
Pope JE; Rampakakis E; Sampalis J
Semin Arthritis Rheum; 2015 Apr; 44(5):499-505. PubMed ID: 25440158
[TBL] [Abstract][Full Text] [Related]
16. The influence of fibromyalgia on achieving remission in patients with long-standing rheumatoid arthritis.
Salaffi F; Gerardi MC; Atzeni F; Batticciotto A; Talotta R; Draghessi A; Di Carlo M; Sarzi-Puttini P
Rheumatol Int; 2017 Dec; 37(12):2035-2042. PubMed ID: 28875224
[TBL] [Abstract][Full Text] [Related]
17. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
18. Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis: A multi-center, prospective cohort study in Japan.
Yamazaki H; Hirano F; Takeuchi T; Amano K; Kikuchi J; Kihara M; Yokoyama W; Sugihara T; Nagasaka K; Hagiyama H; Nonomura Y; Sakai R; Tanaka M; Koike R; Nanki T; Kohsaka H; Miyasaka N; Harigai M
Mod Rheumatol; 2017 Sep; 27(5):787-794. PubMed ID: 27846756
[TBL] [Abstract][Full Text] [Related]
19. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis.
Guyot P; Taylor P; Christensen R; Pericleous L; Poncet C; Lebmeier M; Drost P; Bergman G
Arthritis Res Ther; 2011; 13(6):R204. PubMed ID: 22151924
[TBL] [Abstract][Full Text] [Related]
20. Treatment with the first TNF inhibitor in rheumatoid arthritis patients in the Hellenic Registry of Biologic Therapies improves quality of life especially in young patients with better baseline functional status.
Boubouchairopoulou N; Flouri I; Drosos AA; Boki K; Settas L; Zisopoulos D; Skopouli FN; Papadopoulos I; Iliopoulos A; Kyriopoulos J; Boumpas DT; Athanasakis K; Sidiropoulos P
Clin Exp Rheumatol; 2016; 34(6):999-1005. PubMed ID: 27749220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
